Endoscopy 2025; 57(S 02): S44
DOI: 10.1055/s-0045-1805177
Abstracts | ESGE Days 2025
Oral presentation
EUS tissue acquisition: Tissue is not the only issue 03/04/2025, 12:00 – 13:00 Room 122+123

Intracystic glucose measurement for on-site differentiation between Mucinous and Non-Mucinous Pancreatic Cystic Lesions

A Bruni
1   IRCCS Azienda Ospedaliero Universitaria di Bologna,, Bologna, Italy
,
A Lisotti
2   Imola Hospital S. Maria della Scaletta, Imola, Italy
,
L H Eusebi
3   IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
,
C Ricci
3   IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
,
M Maida
4   Department of Medicine and Surgery, University of Enna ‘Kore’, Enna, Italy
,
P Fusaroli
2   Imola Hospital S. Maria della Scaletta, Imola, Italy
,
G Barbara
5   IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Bologna, Italy
,
R Sadik
6   Sahlgrenska University Hospital, Gothenburg, Sweden
,
N Pagano
7   Ospedale Maggiore di Novara, Novara, Italy
,
P Hedenström
6   Sahlgrenska University Hospital, Gothenburg, Sweden
,
G Marasco
8   IRCCS Azienda Ospedaliero-Universitaria di Bologna, bolo, Italy
› Author Affiliations
 

Aims Pancreatic cystic lesions (PCLs) are frequently detected incidentally and vary from benign to malignant. Accurate differentiation between mucinous (M-PCLs) and non-mucinous PCLs (NM-PCLs) is essential for an appropriate management. Recent studies suggest that intracystic glucose is a promising biomarker for differential diagnosis. This study aims to validate the accuracy of on-site glucose measurement using a glucometer with a cut-off of 50 mg/dL for distinguishing M-PCLs from NM-PCLs.

Methods In this prospective multicenter study, conducted at three European academic hospitals, patients who underwent Endoscopic Ultrasound-Guided Fine Needle Aspiration for PCLs between 2019 and 2020 were included. On-site glucose measurement was performed using a conventional glucometer. Data on demographics, clinical features, EUS findings, and histopathology were collected.

Results Fifty patients were enrolled, with 37 (74%) having glucose levels<50 mg/dL and 13 (26%)≥50 mg/dL. M-PCLs were more common in the<50 mg/dL group (81%) compared to the≥50 mg/dL group (23%, p<0.001). The median Carcinoembryonic Antigen (CEA) was higher in the<50 mg/dL group (146 ng/mL) than in the≥50 mg/dL group (3 ng/mL, p=0.047).

On-site glucose testing<50 mg/dl demonstrated a sensitivity of 93.2%, specificity of 76.5%, and accuracy of 89% for detecting M-PCLs with an Area Under the Curve (AUC) of 0.74 and an OR of 14.29 (95% CI: 3.09 to 65.99, p<0.001). In comparison, CEA>192 ng/mL had a sensitivity of 55.6%, specificity of 87.5%, and accuracy of 75.8% for M-PCLs, with an AUC of 0.65 and an OR of 4.44 (95% CI: 0.74 to 26.68).

Conclusions On-site glucose measurement using a glucometer with a cut-off of<50 mg/dL is a highly accurate, rapid, and cost-effective method for differentiating M-PCLs from NM-PCLs.

Our results validate the glucose cut-off in a multicentric prospective cohort supporting its integration into standard diagnostic protocols for PCLs.



Publication History

Article published online:
27 March 2025

© 2025. European Society of Gastrointestinal Endoscopy. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany